| Targets |
This compound serves as a building block for introducing Boc-protected amino acid residues with a phenyl side chain into peptides and peptidomimetics. The (R) stereochemistry provides specific three-dimensional interactions with target proteins. The phenyl group provides hydrophobic and aromatic interactions. The carboxylic acid group provides a handle for peptide coupling.
|
|---|---|
| ln Vitro |
In vitro, this compound is used as a reagent for synthesizing peptides and peptidomimetics. The carboxylic acid can be coupled to amines using standard peptide coupling chemistry. The Boc group enables selective deprotection for subsequent coupling steps. The phenyl group provides additional functionality for target engagement.
|
| ln Vivo |
In vivo activity data for this compound itself are not applicable, as it is a synthetic intermediate. However, peptides and peptidomimetics synthesized using this intermediate have been evaluated in various in vivo models for therapeutic applications including cancer, neurological disorders, and metabolic diseases.
|
| Enzyme Assay |
For peptide synthesis, the compound is dissolved in DMF or DCM and coupled with amine-containing substrates using standard peptide coupling reagents (e.g., HATU, HOBt, or DCC) in the presence of a base. The reaction is carried out at room temperature for 1-4 hours. The Boc group can be removed by treatment with TFA for subsequent coupling steps.
|
| Cell Assay |
For cell-based studies, peptides or peptidomimetics synthesized using this compound are evaluated in appropriate cell lines. Cells are cultured in DMEM or RPMI-1640 with 10% FBS at 37°C in 5% CO₂. Cells are treated with synthesized compounds at 0.1-100 µM for 24-72 hours. Biological activity is assessed using appropriate assays.
|
| Animal Protocol |
For in vivo studies, compounds synthesized using this intermediate are formulated in suitable vehicles and administered to animal models. Pharmacokinetic studies assess stability and half-life. Efficacy is evaluated in disease models appropriate for the specific compound. Toxicity is monitored by body weight and clinical observations.
|
| ADME/Pharmacokinetics |
(R)-4-(Boc-amino)-5-phenylpentanoic acid has a molecular weight of approximately 293.36 g/mol. It is typically stored as a solid at -20°C under desiccated conditions. The compound is soluble in DMF, DMSO, and other polar organic solvents. The Boc group can be removed under acidic conditions. The phenyl group provides hydrophobic character.
|
| Toxicity/Toxicokinetics |
Acute toxicity data are limited, as it is a synthetic intermediate. Standard laboratory safety practices should be followed. The compound may cause skin and eye irritation upon contact. Proper personal protective equipment should be used. Long-term toxicity studies have not been reported.
|
| Additional Infomation |
This compound is a Boc-protected amino acid building block for peptide synthesis and pharmaceutical research. The (R) stereochemistry provides specific three-dimensional properties. The phenyl group provides additional functionality for target engagement. It is a research intermediate and is not a therapeutic agent itself.
|
| Exact Mass |
293.163
|
|---|---|
| CAS # |
195867-20-0
|
| PubChem CID |
2755985
|
| Appearance |
Typically exists as solids at room temperature
|
| LogP |
3.192
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
21
|
| Complexity |
343
|
| Defined Atom Stereocenter Count |
1
|
| InChi Key |
VPUKBWPBMROHJH-CYBMUJFWSA-N
|
| InChi Code |
InChI=1S/C16H23NO4/c1-16(2,3)21-15(20)17-13(9-10-14(18)19)11-12-7-5-4-6-8-12/h4-8,13H,9-11H2,1-3H3,(H,17,20)(H,18,19)/t13-/m1/s1
|
| Chemical Name |
(4R)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoic acid
|
| HS Tariff Code |
2934.99.9122
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
